Open access
Oct 2026
Clonal hematopoiesis and cell-free DNA characteristics in patients with high-risk large B-cell lymphomas
M. Nylén, L. Meriranta, E. Hiitola et al.
· medRxiv · 0 citations
We have 2 of 14 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Clinical trial
Open access
Sep 2026
Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.
The overall response rate was 95% (95% CI 84-99; 39 of 41 patients), and the most common grade 3-4 adverse events were neutropenia and infections, while epcoritamab showed high activity in first-line treatment for follicular lymphoma.
L. Falchi, J. Vermaat, Joshua D. Brody et al.
· The Lancet Haematology · 0 citations